Business
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
SEATTLE, March 31, 2025--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2024, which include:
About this update from Omeros Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":342,"url":"https://media.zenfs.com/en/business-wire.com/bcd60593e0f06f823aa8131fbc2aaba6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Q3AqnKRLhcutWEzRubPlKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY4NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/bcd60593e0f06f823aa8131fbc2aaba6","width":480,"height":342}},"lazy":false},{"type":"text","content":"– Conference Call Today at 4:30 p.m. ET –","length":41,"tagName":"p","attribs":{}},{"type":"text","content":"SEATTLE, March 31, 2025--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2024, which include:","length":227,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net loss for the fourth quarter of 2024 was $31.4 million, or $0.54 per share, compared to a net loss of $32.2 million, or $0.56 per share for the third quarter of 2024.","length":169,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"For the year ended December 31, 2024, net loss was $156.8 million, or $2.70 per share, compared to a net loss of $117.8 million, or $1.88 per share in the prior year. The change in net loss reflects a $33.2 million decrease in the noncash gain from the remeasurement of the OMIDRIA contract royalty asset, a $6.6 million decrease in interest income earned and a $4.1 million gain on the early extinguishment of debt in December 2023, which were partially offset by a $6.2 million decrease in interest expense as a result of our debt repurchases and refinancing.","length":561,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"At December 31, 2024, we had $90.1 million of cash and short-term investments available for operations and debt servicing, a decrease of $81.7 million from December 31, 2023. We incurred significant cost outlays during the year representing a total of $42.7 million. These cost outlays are comprised of $21.7 million in payments related to repurchasing our convertible senior notes maturing in 2026, $19.1 million in charges related to delivery of narsoplimab drug substance and $1.9 million of costs related to our senior debt transaction.","length":5...